ARONTIER

What ARONTIER does

ARONTIER (아론티어) is a Seoul-based, privately held AI-driven drug discovery company that integrates physics-based modeling with machine learning to design therapeutic candidates across multiple modalities, including antibodies, protein/peptide binders, peptidomimetics, small molecules, and personalized neoantigen mRNA cancer vaccines. The platform is organized into specialized modules — REMEDY for multiomics-based target and drug-repurposing discovery, Small Molecule Designer for generative hit identification, Protein Designer for antibody and binder engineering, RNA Designer for personalized cancer vaccines, Arontier PATH for digital-pathology tumor-microenvironment classification (MFDS approval in progress), and DeepComet for DNA-damage analysis — unified under the AD3 AI drug development platform (beta launched October 2022). The technical stack includes proprietary models AK-Score2, V-Dock, Docking of Millions (DoM), IgPose, and A-Prot, with published benchmarks such as ~12% screening time and 89% top-100 retrieval on 5M-compound libraries (DoM), top-1% enrichment factors of 32.7 and 23.1 on CASF2016/DUD-E, and 31+ peer-reviewed publications (2022–2026) in venues including Nature Communications, Briefings in Bioinformatics, Bioinformatics, J Cheminform, and Sci Rep; IgPose is additionally open-sourced on GitHub (arontier/igpose).

The business model is project-based and partnership-driven rather than SaaS/API: revenue streams comprise contract research and co-development fees from Korean and Chinese pharmaceutical and biotech companies, milestone and IP-sharing arrangements in joint research agreements, large Korean national R&D program grants, and strategic equity investment from corporate backers such as HLB Group (5 billion KRW in July 2024). Named enterprise and institutional customers include HLB Group and affiliates (BioStep, Panagine), Celltrion Pharm, Dongkook Pharmaceutical, Samjin Pharmaceutical, PharmAbcine, Organoid Sciences, Synthenta, Teragenbio, Future Medicine, Aijin, NexEye, Gradient Bioconvergence, Pharmexin, K-Medi Hub, Samsung Seoul Hospital, Yonsei University Medical Center, and the First Affiliated Hospital of Xinxiang Medical University. Pricing is not publicly disclosed, there is no public API or SDK, and the go-to-motion is enterprise field sales.

The company was founded in 2017/2018 (website copyright 2018) by Insuk Sohn (CSO) and Junsu Ko (CEO), is headquartered at 15F, 241, Gangnam-daero, Seocho-gu, Seoul, and has 11–50 employees. It has been selected as a 2025 Korean government Top-tier Startup, featured as one of three 'small giant' companies at BioKorea 2026, and was previously the lead company for the Korean national 2019 AI Drug Development Platform Construction Project, providing a foundation of non-dilutive government capital and academic collaboration with Seoul National University, Ulsan University, and KAIST.

Name

ARONTIER

Legal name

아론티어 주식회사 (Arontier Co., Ltd.)

Website

https://arontier.co

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

ARONTIER is a Seoul-based AI-driven drug discovery company that combines physics-based modeling with machine learning to design antibodies, protein binders, small molecules, and RNA therapeutics for pharmaceutical, biotech, hospital, and academic partners.

Ownership category

akta.pro rank

Product category

AI Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI drug discovery
• Precision medicine platform
• Antibody design services
• Small molecule discovery
• Digital pathology AI

Headquarters

HQ city

Seocho

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Equity investment / capital raise: Receives strategic equity investment from corporate backers (e.g., 5 billion won investment from HLB Group announced 2024-07-02). This is a financing-related inflow rather than operating revenue, but indicative of strategic capital partnerships.
2. Government R&D grants and national project funding: Receives funding from Korean national R&D programs (2019 AI Drug Development Platform program — ~11.25 billion KRW per project over 3 years; AI Data-driven Bio-Leading Technology Development program 2024; Next-generation ADC manufacturing national project 2025; Data Voucher program 2025). Funds awarded to Arontier as lead or participating organization.
3. Joint research and co-development contracts with pharma/biotech: Generates revenue through joint research agreements, MOUs, and co-development contracts with pharmaceutical and biotech companies (e.g., Celltrion Pharm, Dongkook Pharmaceutical, Samjin Pharmaceutical, Synthenta, Pharmexin, Gradient Bioconvergence, PharmAbcine, Aijin, Future Medicine, Teragenbio, NexEye). These arrangements typically combine service fees, milestone payments, and IP sharing.
4. Platform-as-a-Service / contract research services: Provides AI-based small molecule design and synthesis services for partners (e.g., Synthenta small molecule design and synthesis service) and offers technology-platform access for customer R&D programs. Model is project-based / contract research rather than off-the-shelf SaaS.
5. Hospital and academic collaboration contracts: Generates research contracts with hospitals and academic institutions (Samsung Seoul Hospital, Yonsei University Medical Center Industry-Academic Cooperation Foundation, Gangneung National University, The First Affiliated Hospital of Xinxiang Medical University, Chinese hospitals). Likely grant- or milestone-based.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Arontier is an AI-driven drug discovery company that operates an integrated precision medicine platform combining physics-based modeling with machine learning to design antibodies, protein/peptide binders, peptidomimetics, RNA therapeutics, and small-molecule drugs. The company provides joint research, co-development, and contract research services to pharmaceutical, biotech, hospital, and academic partners, and sells platform access (AD3) along with diagnostic digital pathology products (Arontier PATH, DeepComet).

Product overview

Arontier offers an integrated AI-driven precision medicine platform composed of multiple specialized modules that together cover the full drug discovery pipeline from target identification to candidate design. The platform's foundation rests on REMEDY (multiomics target and drug candidate discovery), which feeds into three designer modules: Small Molecule Designer (for small-molecule drug discovery via generative AI and high-throughput virtual screening including the Docking of Millions system), Protein Designer (for antibody and protein binder design, including AllomorphicANTIBODY and AI-based Deimmunization), and RNA Designer (for personalized neoantigen cancer vaccines). Complementary digital pathology products Arontier PATH (AI tumor microenvironment classifier; MFDS approval in progress) and DeepComet (AI DNA damage analysis) extend the platform into diagnostic and safety applications. The proprietary AD3 platform (beta launched October 2022) serves as the user-facing AI drug development platform integrating these capabilities. Together, these modules position Arontier as a full-stack AI drug discovery company addressing incurable and rare diseases.

Differentiator

Problem solved

Functional benefit

Brands

• REMEDY: AI-based multiomics platform for discovery of novel targets and drug candidates.
• SMALL MOLECULE DESIGNER
• PROTEIN DESIGNER
• RNA DESIGNER
• Arontier PATH
• DeepComet
• AD3

Products and services

• REMEDY Discovery platform that uses multiomics data (transcriptomics, genomics, proteomics) and LINCS-based signature reversal to identify novel drug targets and repurpose existing compounds for new indications. Sold to pharmaceutical, biotech, hospital, and academic research partners.
• Small Molecule Designer AI platform for de novo small-molecule drug discovery combining generative molecular design, high-throughput virtual screening via the Docking of Millions (DoM) system, and medicinal chemistry expertise. For pharmaceutical and biotech R&D partners.
• Protein Designer De novo design platform for antibodies and protein/peptide binders using generative deep learning, protein-protein interaction prediction, molecular dynamics simulations, and AI-based deimmunization. Supports the AllomorphicANTIBODY antibody project. For pharma and biotech R&D teams.
• RNA Designer AI platform for personalized neoantigen cancer vaccine design, with proprietary mRNA design achieving 10x higher expression. For cancer vaccine developers, biotech, and pharma partners.
• Arontier PATH Digital pathology AI biomarker that classifies the tumor microenvironment from hematoxylin and eosin-stained whole-slide histopathology images, supporting cancer-associated fibroblast (CAF) characterization. Used in hospital and clinical research settings; MFDS approval in progress.
• DeepComet AI-powered DNA damage analysis tool using comet assay-based methods for genotoxicity assessment in drug safety evaluation. For pharmaceutical R&D and safety pharmacology teams.
• AD3 AI Drug Development Platform Integrated user-facing AI drug development platform launched in beta in October 2022, providing AI-based drug candidate screening capabilities to pharmaceutical and biotech research partners.
• CAF-based eRNA Target Discovery AI Platform AI platform for cancer-associated fibroblast (CAF)-derived enhancer RNA (eRNA) target discovery, extending multiomics target identification capabilities into cancer therapeutics. Unveiled at AACR 2026.

Quantifiable outcome

• Reduces candidate development time from an industry average of ~5 years to as little as ~1 year
• +4 more outcomes

Named customers19 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability12 records

Feature14 records

Partnerships

22 partnerships are on record, tiered minor and core.

• SynthentaminorStrategic or Co-development Partner · 17 March 2026Arontier and Synthenta are conducting an AI-based small molecule design and synthesis service collaboration.
• Organoid Sciences (오가노이드사이언스)coreStrategic or Co-development Partner · 16 January 2026Organoid Sciences and Arontier announced an expansion of AI-based non-clinical evaluation technology collaboration.
• HLB Panagine (HLB파나진)coreStrategic or Co-development Partner · 11 December 2025HLB Panagine launched a spatial proteome analysis service using Arontier's AI technology, building on HLB Group's incorporation of Arontier AI for diagnostics and new drugs.
• Celltrion Pharm (셀트리온제약)coreStrategic or Co-development Partner · 26 March 2025AI new drug development company Arontier and Celltrion Pharm entered into a new drug development agreement using Arontier's AI drug development platform.
• PharmAbcinecoreStrategic or Co-development Partner · 10 February 2025PharmAbcine and Arontier announced a partnership to develop an AI-driven antibody-based drug development platform (announced 2025-02-10).
• Spark BiopharmaminorStrategic or Co-development Partner · 10 February 2025Spark Biopharma is referenced alongside Odyssey Therapeutics and Arontier in the PharmAbcine/Arontier announcement context, for collaboration to develop autoimmune and inflammatory disease drugs using pDOS technology within Odyssey's research strategy (Odyssey raised over USD 700 million in funding).
• Pharmexin (파멥신)coreStrategic or Co-development Partner · 10 February 2025Pharmexin is incorporating Arontier's AI technology to build a next-generation antibody development platform.
• Dongkook Pharmaceutical (동국제약)coreStrategic or Co-development Partner · 6 March 2024Dongkook Pharmaceutical and Arontier signed an agreement for joint research on AI-based advanced pharmaceutical development.
• Teragenbio (테라젠바이오)coreStrategic or Co-development Partner · 17 January 2024Teragenbio and Arontier jointly develop an AI-based personalized cancer vaccine design platform.
• HLB BioStep (HLB바이오스텝)coreStrategic or Co-development Partner · 27 December 2023HLB BioStep and Arontier signed an agreement for full-scale ('all-directional') cooperation to accelerate AI new drug development.
• Samjin Pharmaceutical (삼진제약)coreStrategic or Co-development Partner · 25 October 2023Samjin Pharmaceutical entered into an AI-based immune anticancer drug joint research contract with Arontier.
• Gradient Bioconvergence (그래디언트바이오컨버전스)minorStrategic or Co-development Partner · 6 October 2023Gradient Bioconvergence signed a new drug development business agreement with Arontier.
• Aijin (아이진)minorStrategic or Co-development Partner · 8 June 2023Agreement between Aijin and Arontier to develop AI-based mRNA vaccine.
• K-Medi Hub (케이메디허브)coreStrategic or Co-development Partner · 17 May 2023Arontier and K-Medi Hub are jointly developing AI-based patient-customized innovative new drugs. Subsequent 'new drug candidate discovery' workshop held December 2025.
• Professor Park Jong-min's team, Kangwon National University (박종민 강원대 교수팀)minorStrategic or Co-development Partner · 5 April 2023Arontier signed a joint research and development contract with Professor Park Jong-min's team at Kangwon National University for CAF-targeted new drug development.
• NexEye (넥스아이)minorStrategic or Co-development Partner · 16 March 2023NexEye and Arontier signed an MOU for joint development of AI-based antibody new drugs.
• Samsung Seoul Hospital (삼성서울병원)coreStrategic or Co-development Partner · 20 October 2022Samsung Seoul Hospital and Arontier signed an MOU for AI-driven innovative new drug development.
• The First Affiliated Hospital of Xinxiang Medical University (新乡医学院第一附属医院)minorStrategic or Co-development Partner · 13 February 2020Arontier signed a joint new drug research agreement with the First Affiliated Hospital of Xinxiang Medical University (China).
• Chinese hospital partner (中 병원)minorStrategic or Co-development Partner · 11 February 2020Arontier collaborated with a Chinese hospital partner to develop new drugs targeting the tumor microenvironment.
• Yonsei University Medical Center Industry-Academic Cooperation Foundation (연세의료원 산학협력단)coreStrategic or Co-development Partner · 16 January 2020Arontier and Yonsei University Medical Center's Industry-Academic Cooperation Foundation signed a joint new drug research agreement.
• Future Medicine (퓨쳐메디신)coreStrategic or Co-development Partner · 8 January 2020Joint research on immune anticancer drugs applying Arontier's AI new drug development platform; subsequent collaboration in May 2023 to apply AI to nucleoside-based new drug development.
• Seoul National University, Ulsan University, and KAIST (Korea Advanced Institute of Science and Technology)coreStrategic or Co-development Partner · 1 January 2019Arontier was selected as the lead company for the 'Drug Candidate Discovery' area of the Korean national 2019 AI Drug Development Platform Construction Project, with joint research partners Seoul National University, Ulsan University, and KAIST. Total per-project funding ~11.25 billion KRW over 3 years (2+1).

Scale indicators10 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• XtalPi: Asia-based AI + physics-driven drug discovery platform with comparable small-molecule design, virtual screening, and CRO partnership model; directly competes for the same Asian pharma enterprise customers Arontier serves.
• Insilico Medicine: End-to-end AI drug discovery company with target identification (PandaOmics), generative chemistry (Chemistry42), and clinical assets — directly comparable to Arontier's REMEDY-to-RNA-Designer pipeline and to its claim of compressing 5-year timelines to ~1 year.
• Recursion Pharmaceuticals: AI-driven drug discovery combining high-throughput biology with ML for target and candidate identification across multiple modalities. Comparable in modality breadth, multi-pharma partnership model, and digital pathology-adjacent phenomics.
• BenevolentAI: AI platform for target identification and drug discovery with focus on multiomics and knowledge graphs; analogous to Arontier's REMEDY (LINCS-based signature reversal) target-discovery approach.
• Standigm: Korean AI drug discovery company offering end-to-end target identification, lead generation, and candidate design — a direct domestic peer competing for the same Korean pharma partners and national R&D programs as Arontier.
• Atomwise: AI small-molecule discovery platform (AtomNet) for hit identification and lead optimization through virtual screening. Directly comparable to Arontier's Small Molecule Designer and DoM offering.
• Schrödinger: Physics-based plus ML drug discovery platform with comparable small-molecule virtual screening and protein-ligand binding prediction capabilities. Arontier's DoM, AK-Score2 and V-Dock mirror Schrödinger LiveDesign and FEP+ workflows; both target pharma/biotech enterprise customers.

Emerging players

• AIGEN Sciences: Korean AI-driven drug discovery startup focused on generative chemistry and protein design; an emerging domestic peer with partial overlap in small-molecule and protein-ligand modeling capabilities.
• Adagene: AI-driven antibody discovery platform (POWER-based) with comparable antibody design and deimmunization capabilities to Arontier's Protein Designer and AllomorphicANTIBODY module.
• Pharos iBio: Korean AI-target-discovery biotech using omics and knowledge graphs; comparable to Arontier's REMEDY multiomics target discovery module and competing for the same Korean pharma collaborations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• GitHubgithub.com/arontier/igpose

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARONTIER